Bradley Duffy

Array ( [id] => 16815750 [patent_doc_number] => 11000550 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/903882 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 12224 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452633 [patent_doc_number] => 20200362059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => Acceptor Framework for CDR Grafting [patent_app_type] => utility [patent_app_number] => 16/879978 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557232 [patent_doc_number] => 20210002380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => Humanized Anti-CD70 Binding Agents and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/869322 [patent_app_country] => US [patent_app_date] => 2020-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16799105 [patent_doc_number] => 10994021 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-05-04 [patent_title] => Tetravalent antibody-drug conjugates and use thereof [patent_app_type] => utility [patent_app_number] => 16/862042 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 10153 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581458 [patent_doc_number] => 20210015860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/845030 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545340 [patent_doc_number] => 11718680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists [patent_app_type] => utility [patent_app_number] => 16/820504 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 25 [patent_no_of_words] => 53157 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 400 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16093533 [patent_doc_number] => 20200200753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS [patent_app_type] => utility [patent_app_number] => 16/806037 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611585 [patent_doc_number] => 20220153864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Novel Fusion Proteins Specific for CD137 and GPC3 [patent_app_type] => utility [patent_app_number] => 17/433155 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268840 [patent_doc_number] => 20200270327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/798104 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2583 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268841 [patent_doc_number] => 20200270328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS OF TREATMENTS USING CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/798151 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2594 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18779113 [patent_doc_number] => 11820806 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof [patent_app_type] => utility [patent_app_number] => 16/798059 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 28 [patent_no_of_words] => 73739 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 416 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569103 [patent_doc_number] => 20210008109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 16/794119 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109570 [patent_doc_number] => 20230002450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner [patent_app_type] => utility [patent_app_number] => 17/431664 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743305 [patent_doc_number] => 10968280 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Binding agents binding to PD-L1 and CD137 and use thereof [patent_app_type] => utility [patent_app_number] => 16/779011 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 38 [patent_no_of_words] => 43138 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 400 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397316 [patent_doc_number] => 20200338174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => METHODS FOR ACTIVATING IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 16/779042 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206596 [patent_doc_number] => 20200239586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => Fn14 Binding Proteins and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/776349 [patent_app_country] => US [patent_app_date] => 2020-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16776349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523815 [patent_doc_number] => 20200397895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/752231 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16752231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282704 [patent_doc_number] => 20200276306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Glycan-Interacting Compounds and Methods of Use [patent_app_type] => utility [patent_app_number] => 16/742434 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503444 [patent_doc_number] => 20220096546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Modified Cell Expansion and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/420066 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315131 [patent_doc_number] => 11629200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Means and methods for counteracting myeloproliferative or lymphoproliferative disorders [patent_app_type] => utility [patent_app_number] => 16/733376 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 27 [patent_no_of_words] => 39498 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733376 [rel_patent_id] =>[rel_patent_doc_number] =>)